NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









LISCure Biosciences Inc.

LISCure Biosciences Inc.

Private
South KoreaHealthcare & Life Scienceshttps://liscure.bio/

Last Round

Private Equity

Jan 10, 2025

Est. Valuation

$80.6M

Total Funding Raised

$43.54M

Company Overview

LISCure Biosciences Inc. is a clinical-stage biotechnology company that develops bacteria-mediated cancer immunotherapy and oral microbiome therapeutics for oncology, liver diseases, neuroscience, and immunology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

microbiome therapeuticslive biotherapeutic productsLBPgut-liver axisblood-brain barrier shuttleBBB shuttlefunctional probioticsnutraceuticalsbacteria-mediated immunotherapydrug delivery platformmicrobiome drug discoverybiotech licensinggut healthmicrobiome startups

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

LISCure Biosciences Inc. Comparables

Compare LISCure Biosciences Inc. with similar companies based on industry and business-model similarity.

LISCure Biosciences Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Exeliom Biosciences
80%
EnteroBiotix
78%
MRM Health
77%

LISCure Biosciences Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private EquityJan 10, 2025
StrategicAug 1, 2021
Series BFeb 25, 2021
StrategicDec 11, 2020
StrategicOct 28, 2020
Strategic
Oct 21, 2020

Key People

Founding team and executive leadership

Kyoungsub Song

Chief Technology Officer

Executive Team

LISCure Biosciences Inc. Investors

Notable investors and investment history

LISCure Biosciences Inc. investors
InvestorRounds
IGIS Asset ManagementPrivate Equity
KB SecuritiesSeed
Dt& InvestmentPrivate Equity
Shinhan SecuritiesSeed
Yuanta InvestmentPrivate Equity
InterValue PartnersPrivate Equity
NHN InvestmentSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 1, 2021

    Mayo Clinic participated in the strategic round.

  • Jul 25, 2019

    $5M raised from KB Securities, Shinhan Securities, and NHN Investment.

LISCure Biosciences Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

LISCure Biosciences Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about LISCure Biosciences Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth Korea
Employee Range6
Year Founded2018
Last FundingJan 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.